Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Hope S. Rugo, MD

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.

Breast Cancer

Harry D. Bear, MD, PhD

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Breast Cancer

Prudence Francis, MD, and Hope Rugo, MD

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08, "Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial."

Jul

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy

Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, Discuss the SOFT Trial

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality

Patients With Prostate Cancer Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Update on LEANer Trial in Patients With Breast Cancer

Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors Long-Term Outcomes

New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma